Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSEAMERICAN:CLDI NASDAQ:CLSD NASDAQ:LSTA OTCMKTS:PVOTF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDICalidi Biotherapeutics$1.55-2.5%$2.52$1.41▼$46.68$5.45M1.07156,476 shs163,279 shsCLSDClearside Biomedical$3.98-8.7%$5.10$3.32▼$19.95$22.83M2.0576,099 shs50,927 shsLSTALisata Therapeutics$2.37-2.5%$2.44$1.87▼$4.20$21.28M1.0439,339 shs14,944 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDICalidi Biotherapeutics-2.52%-3.13%-3.73%-83.00%-87.21%CLSDClearside Biomedical-8.72%-8.92%-20.06%-70.02%-79.75%LSTALisata Therapeutics-2.47%-5.95%+3.49%-12.55%-22.55%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLDICalidi Biotherapeutics$1.55-2.5%$2.52$1.41▼$46.68$5.45M1.07156,476 shs163,279 shsCLSDClearside Biomedical$3.98-8.7%$5.10$3.32▼$19.95$22.83M2.0576,099 shs50,927 shsLSTALisata Therapeutics$2.37-2.5%$2.44$1.87▼$4.20$21.28M1.0439,339 shs14,944 shsPVOTFBetterLife Pharma$0.00$0.03▼$0.38$21.70MN/A52,703 shs198,200 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLDICalidi Biotherapeutics-2.52%-3.13%-3.73%-83.00%-87.21%CLSDClearside Biomedical-8.72%-8.92%-20.06%-70.02%-79.75%LSTALisata Therapeutics-2.47%-5.95%+3.49%-12.55%-22.55%PVOTFBetterLife Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLDICalidi Biotherapeutics 0.00N/AN/AN/ACLSDClearside Biomedical 2.17Hold$63.001,482.91% UpsideLSTALisata Therapeutics 2.33Hold$23.50891.56% UpsidePVOTFBetterLife Pharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CLDI, CLSD, PVOTF, and LSTA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025LSTALisata TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LSTALisata TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)8/21/2025LSTALisata TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.007/18/2025CLSDClearside BiomedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$75.007/18/2025CLSDClearside BiomedicalChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral7/18/2025CLSDClearside BiomedicalStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$30.007/17/2025CLSDClearside BiomedicalJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/17/2025CLSDClearside BiomedicalNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeModerate Buy ➝ Hold$45.007/15/2025LSTALisata TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $32.00(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLDICalidi Biotherapeutics$50K106.33N/AN/A$0.89 per share1.74CLSDClearside Biomedical$1.66M12.56N/AN/A($7.68) per share-0.52LSTALisata Therapeutics$1M20.76N/AN/A$3.49 per share0.68PVOTFBetterLife PharmaN/AN/AN/AN/A$0.01 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLDICalidi Biotherapeutics-$22.14MN/A0.00N/AN/AN/A-5,152.88%-175.92%N/ACLSDClearside Biomedical-$34.35M-$5.55N/AN/AN/A-665.19%N/A-124.15%11/11/2025 (Estimated)LSTALisata Therapeutics-$19.99M-$2.23N/AN/AN/AN/A-69.68%-59.44%11/11/2025 (Estimated)PVOTFBetterLife Pharma-$14.78MN/AN/AN/AN/AN/A-205.15%-147.23%N/ALatest CLDI, CLSD, PVOTF, and LSTA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025CLSDClearside Biomedical-$1.80-$0.90+$0.90-$0.06$0.50 million$0.49 million8/7/2025Q2 2025LSTALisata Therapeutics-$0.65-$0.54+$0.11-$0.54N/A$0.07 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLDICalidi BiotherapeuticsN/AN/AN/AN/AN/ACLSDClearside BiomedicalN/AN/AN/AN/AN/ALSTALisata TherapeuticsN/AN/AN/AN/AN/APVOTFBetterLife PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLDICalidi Biotherapeutics0.401.131.13CLSDClearside BiomedicalN/A3.873.87LSTALisata TherapeuticsN/A5.775.77PVOTFBetterLife PharmaN/A3.623.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLDICalidi Biotherapeutics12.53%CLSDClearside Biomedical18.75%LSTALisata Therapeutics8.94%PVOTFBetterLife PharmaN/AInsider OwnershipCompanyInsider OwnershipCLDICalidi Biotherapeutics6.70%CLSDClearside Biomedical6.70%LSTALisata Therapeutics9.60%PVOTFBetterLife Pharma34.77%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLDICalidi Biotherapeutics383.43 million3.20 millionN/ACLSDClearside Biomedical305.24 million4.89 millionOptionableLSTALisata Therapeutics308.76 million7.92 millionNot OptionablePVOTFBetterLife PharmaN/A171.41 millionN/ANot OptionableCLDI, CLSD, PVOTF, and LSTA HeadlinesRecent News About These CompaniesBetterLife Pharma Inc.May 19, 2025 | barrons.comBetterLife appoints Steven Sangha to board of directorsApril 1, 2025 | markets.businessinsider.comBetterLife Pharma Achieves Key Cardiac Safety MilestoneNovember 25, 2024 | markets.businessinsider.comBetterLife Pharma Inc BETRNovember 2, 2024 | morningstar.comMOptimistic Buy Rating for BridgeBio Pharma’s BBP-812: Promising Phase 1/2 Results in Canavan Disease TherapyOctober 25, 2024 | markets.businessinsider.comBridgeBio Pharma’s BBP-812 Trial Shows Promise for Canavan Disease Amidst Focus on AcoramidisOctober 25, 2024 | markets.businessinsider.comBetterLife Obtains Favourable Genotoxicity Data for Oral BETR-001October 23, 2024 | tmcnet.comWith election nearing, BMO analysts don't expect major pharma shake-ups from either candidateOctober 14, 2024 | fiercepharma.comFAbortion, immigration, drug prices: Where Missouri’s candidates for U.S. Senate stand on the issuesOctober 13, 2024 | msn.comDemocrats snatch a major political football away from Republicans: freedomAugust 28, 2024 | yahoo.comRAMM Pharma Corp. (RAMM.CN)August 22, 2024 | uk.finance.yahoo.com‘Their skin was peeling off from the chemical burns’: Andhra reactor blast that killed 14 leaves trail of broken homesAugust 21, 2024 | indianexpress.comIRewarding careers for animal loversAugust 13, 2024 | deccanherald.comDState, city leaders announce deal for quantum technology facility on Chicago’s South SideJuly 27, 2024 | courthousenews.comC$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management DrugsApril 26, 2024 | msn.comJardiance and Ofev propel Boehringer’s human pharma salesApril 17, 2024 | msn.comVertex Pharma scientist talks about the long road to developing non-addictive painkillersApril 15, 2024 | abcnews.go.comPharmacy defends Eli Lilly off-label drug suitApril 11, 2024 | lifesciencesipreview.comLBetterLife To Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceApril 11, 2024 | tmcnet.comVictory Over Big Pharma Will Take More Than the IRAApril 4, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLDI, CLSD, PVOTF, and LSTA Company DescriptionsCalidi Biotherapeutics NYSEAMERICAN:CLDI$1.55 -0.04 (-2.52%) Closing price 10/10/2025 04:10 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 10/10/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.Clearside Biomedical NASDAQ:CLSD$3.98 -0.38 (-8.72%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$4.08 +0.10 (+2.39%) As of 10/10/2025 06:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Lisata Therapeutics NASDAQ:LSTA$2.37 -0.06 (-2.47%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$2.40 +0.02 (+1.05%) As of 10/10/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.BetterLife Pharma OTCMKTS:PVOTFBetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
